Anzeige
Mehr »
Montag, 26.01.2026 - Börsentäglich über 12.000 News
Gold über 5.000 USD verändert die Wirtschaftlichkeit grundlegend!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
122 Leser
Artikel bewerten:
(0)

Biomaterials Market worth $68.93 billion by 2030 | MarketsandMarkets

DELRAY BEACH, Fla., Jan. 26, 2026 /PRNewswire/ -- According to MarketsandMarkets, the Biomaterials Market is projected to grow from about USD 48.36 billion in 2025 to USD 68.93 billion by 2030, at a CAGR of 7.3%.

MarketsandMarkets Logo

Browse 908 market data Tables and 50 Figures spread through 663 Pages and in-depth TOC on "Biomaterials Market - Global Forecast to 2030"

Biomaterials Market Size & Forecast:

  • Market Size Available for Years: 2024-2030
  • 2025 Market Size: USD 48.36 billion
  • 2030 Projected Market Size: USD 68.93 billion
  • CAGR (2025-2030): 7.3%

Biomaterials Market Trends & Insights:

  • Metallic biomaterials are projected to show the highest CAGR of 7.6% between 2025 and 2030.
  • The orthopaedic segment is expected to dominate the global biomaterials market in 2024 with a CAGR of 34.9%.
  • The Asia Pacific is the fastest-growing regional segment with a CAGR of 7.8% during the forecast period.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=393

The growth of the global biomaterials market is due to several key factors, including the rising advancements in smart, biocompatible, and 3D-printed biomaterials and advancements in healthcare facilities and systems.

Advances in material engineering, surface treatments, and manufacturing processes are making implants tougher, more body-friendly, and reliable over the long haul. At the same time, stricter regulations and the push toward value-based healthcare are nudging manufacturers to not only innovate but also prove their products' safety, durability, and real-world performance.

By type, the metallic biomaterials segment accounted for the largest share of the global biomaterials market in 2024.

the biomaterials market is segmented into metallic (stainless steel, titanium & titanium alloys, cobalt-chrome alloys, gold, silver, magnesium, and other metallic biomaterials), polymeric (polymethylmethacrylate, polyethylene, polyester, polyvinylchloride, silicone rubber, nylon, polyetheretherketone, other polymeric biomaterials), ceramic (calcium phosphate, zirconia, aluminum oxide, calcium sulfate, carbon and glass), and natural (hyaluronic acid, collagen, fibrin, cellulose, chitin, alginate, gelatin, chitosan, silk, other natural biomaterials). The metallic biomaterials segment dominated the market share in 2024, due to the heavy reliance on metals for crafting key medical devices in the cardiovascular, dental, and orthopedic fields. With a growing global geriatric population, demand for these devices is surging, as older adults face heightened risks for orthopedic, dental, ophthalmologic, neurological, and cardiovascular conditions.

Request Sample Pages@https://www.marketsandmarkets.com/requestsampleNew.asp?id=393

By application, Orthopedics is expected to be the fastest-growing application segment

The global biomaterials market is segmented by application into orthopedic, cardiovascular, dental, plastic surgery, urinary applications, wound healing, tissue engineering, ophthalmology, neurological/central nervous system, and other applications. In 2024, the orthopedic segment claimed the largest share of the global biomaterials market. This dominance stems from surging demand driven by an aging population, rising obesity rates, and active lifestyles that increase injury risks, alongside breakthroughs in bioresorbable implants and 3D-printed custom prosthetics that enhance recovery times and patient outcomes.

North America accounted for the largest regional share in the global biomaterials market in 2024.

North America accounted for the largest share of regional revenues and is the primary engine of growth. The region's dominance reflects its dense concentration of medical-device and biopharma headquarters, academic medical centers, and specialized surgical and research hospitals, as well as strong FDA oversight and rapid uptake of advanced implant, regenerative, and drug-eluting biomaterial technologies. Large orthopedic, cardiovascular, and dental implant pipelines, robust NIH and venture funding for regenerative medicine, and an active clinical-trials ecosystem further cement the US as the leading biomaterials innovation hub within North America, while Canada contributes a smaller but important share, driven by expanding hospital infrastructure and growing investment in tissue-engineering and polymeric biomaterials manufacturing.

Inquire Before Buying@https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=393

Top Companies in Biomaterials Market:

The Top Companies in Biomaterials Market include BASF SE (Germany), Covestro AG (Germany), Celanese Corporation (US), Carpenter Technology Corporation (US), DSM (Netherlands), Corbion NV (Netherlands), Evonik Industries AG (Germany), Victrex Plc (UK), CeramTec GmbH (Germany), Mitsubishi Chemical Group Corporation (Japan), CoorsTek Inc. (US), Berkeley Advanced Biomaterials (US), CAM Bioceramics B.V. (Netherlands), Zeus Company Inc. (US), AMETEK Inc. (US), and GELITA AG (Germany).

Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting

Related Reports:

Collagen & Gelatin Market - Global Forecast to 2030

Orthopedic Devices Market - Global Forecast to 2030

Dental Imaging Market - Global Forecast to 2030

Dental Consumables Market - Global Forecast to 2030

Oral Care Market - Global Forecast to 2030

About MarketsandMarkets

MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biomaterials-market-worth-68-93-billion-by-2030--marketsandmarkets-302668807.html

© 2026 PR Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.